Results 41 to 50 of about 1,624 (170)

Image_4_OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma.tif

open access: yes, 2021
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with a five-year survival rate of less than 10%. Gemcitabine (GEM) is the most commonly used drug for PDAC chemotherapy. However, a vast majority of patients with PDAC develop
Yizhang Zhou (11651926)   +10 more
core   +1 more source

Clinical and bi-genomic DNA findings of patients suspected to have mitochondrial diseases

open access: yesFrontiers in Genetics, 2023
Background: Mitochondrial diseases are the most common group of inherited metabolic disorders, causing difficulties in definite diagnosis due to clinical and genetic heterogeneity. Clinical components are predominantly associated with pathogenic variants
Asuman Gedikbasi   +15 more
doaj   +1 more source

Image_2_OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma.tif

open access: yes, 2021
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with a five-year survival rate of less than 10%. Gemcitabine (GEM) is the most commonly used drug for PDAC chemotherapy. However, a vast majority of patients with PDAC develop
Yizhang Zhou (11651926)   +10 more
core   +1 more source

Metabolism‐Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53‐Mutant Colon Cancer

open access: yesAdvanced Science, 2022
Although targeting cancer metabolism is a promising therapeutic strategy, clinical success depends on accurate molecular and metabolic subtyping. Here, this study reports two metabolism‐based molecular subtypes associated with the ketogenic treatment of ...
Meng Tang   +23 more
doaj   +1 more source

Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo

open access: yesJournal of Lipid Research, 2018
The ketogenic diet (KD) is a high-fat, very-low-carbohydrate diet that triggers a fasting state by decreasing glucose and increasing ketone bodies, such as β-hydroxybutyrate (βHB).
Jie Zhang   +7 more
doaj   +1 more source

LncRNA OXCT1-AS1 promotes the proliferation of non-small cell lung cancer cells by targeting the miR-195/CCNE1 axis

open access: yesTranslational Cancer Research, 2022
Long non-coding RNAs (lncRNAs) are involved in various biological processes in non-small cell lung cancer (NSCLC). This study aimed to investigate the key lncRNA OXCT1-AS1/miR-195/CCNE1 axis in the development of NSCLC and its potential molecular mechanism.LncRNA OXCT1-AS1 is considered to be a competitive endogenous RNA (ceRNA) and its potential ...
Wang, Dapeng   +6 more
openaire   +2 more sources

OXCT1‐driven succinylation of PSMG3 stabilizes the proteasome to facilitate picornavirus replication

open access: yesiMetaOmics, EarlyView.
Upon entering the pig, foot‐and‐mouth disease virus (FMDV) regulates host glycolysis and the citrate cycle by modulating the expression of metabolic enzymes, resulting in changes in post‐translational modifications (PTMs) including succinylation, lactylation, crotonylation, acetylation, and phosphorylation.
Huisheng Liu   +9 more
wiley   +1 more source

Muscle Hmgcs2 and Oxct1 expression in GFP- and FATP1-mice.

open access: yes, 2014
(A) The Hmgcs2 mRNA levels relative to Actb and (C) Oxct1 mRNA levels relative to Rn18s were analyzed in the gastrocnemius muscles of GFP- and FATP1-female mice fed a chow or high-fat diet (HFD).
Anna M. Gómez-Foix (334938)   +11 more
core   +1 more source

Bioinformatic analysis of the gene expression profile in muscle atrophy after spinal cord injury

open access: yesScientific Reports, 2021
Spinal cord injury (SCI) is often accompanied by muscle atrophy; however, its underlying mechanisms remain unclear. Here, the molecular mechanisms of muscle atrophy following SCI were investigated.
Hui Huang   +8 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy